Stroke Meeting Ends, New Questions Arise

My questions are:
1. When the hell are you going to work on stopping the neuronal cascade of death?
2. When will you pick an objective diagnosis tool? so that people don't wait in emergency rooms until their symptoms are obvious.
3. When will you publically publish stroke protocols for ERs, rehab departments so patients can make informed decisions about where to go and where to avoid?
Dr. Sacco, as president of the ASA you are in position to drive these answers if you have any competency to meet survivor needs.  Its been 2 months since this ended, you should have focus groups working on solving these problems and a first report soon.


http://www.medpagetoday.com/Cardiology/Strokes/37322?
The International Stroke Conference has wrapped up in Honolulu, but the results of many of the clinical trials presented will be reverberating for a long time to come, says Ralph L. Sacco, MD, in this exclusive InFocus interview.
Just about all of the trials that tested an endovascular therapeutic approach to ischemic stroke could not show the intra-arterial technique was better than standard intravenous thrombolysis with tissue plasminogen activator (tPA).
But these trials were not done in vain, said Sacco, a former president of the American Heart Association and chair of neurology at the University of Miami Miller School of Medicine. They raise important questions that need to be answered going forward, and they pave the way for testing newer devices and drugs.
A few trials testing secondary stroke prevention had conflicting findings, but Sacco explained to MedPage Today cardiology editor Chris Kaiser how they might be interpreted.
And finally, there was some promising news regarding the treatment of intracerebral hemorrhagic stroke, which, Sacco said, is particularly welcome for this devastating and challenging type of stroke.